Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 301–400 of 4,275
Physiological and pathological consequences of cellular senescence
Burton, D. G. A., & Krizhanovsky, V. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1691-3 · Cited by 253
“Although a number of these secretory factors may be specific to senescence of certain cell types or the method of senescence induction, the commonly secreted factors are often referred to as the senescence-associated secretory phenotypes [33].”
BackgroundPathomechanism of intervertebral disc degeneration
Oichi, T., Taniguchi, Y., Oshima, Y., Tanaka, S., & Saito, T. (2020) · JOR SPINE · doi:10.1002/jsp2.1076 · Cited by 250
Blagosklonny, M. V. (2012) · Aging · doi:10.18632/aging.100443 · Cited by 251
“Noteworthy, SASP as a marker of senescence [91-99] is an example of hyperfunction.”
BackgroundTabibian, J. H., O'Hara, S. P., Splinter, P. L., Trussoni, C. E., & LaRusso, N. F. (2014) · Hepatology · doi:10.1002/hep.26993 · Cited by 241
Protective Role of Polyphenols against Vascular Inflammation, Aging and Cardiovascular Disease
Serino, A., & Salazar, G. (2018) · Nutrients · doi:10.3390/nu11010053 · Cited by 250
“In fact, senescence induced by oncogenic Ras, which causes genotoxic stress, resulted in the expression of SASP components [17], while senescence induced by overexpressing tumor suppressor p16 does not induce the SASP in human epithelial cells [18].”
BackgroundThe hallmarks of fibroblast ageing
Tigges, J., Krutmann, J., Fritsche, E., Haendeler, J., Schaal, H., Fischer, J. W., Kalfalah, F., Reinke, H., Reifenberger, G., Stühler, K., et al. (2014) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2014.03.004 · Cited by 250
“, 2003) and increased secretion of cytokines and other biologically active proteins (Coppe et al., 2008).”
BackgroundInfluentialWalaszczyk, A., Dookun, E., Redgrave, R., Tual‐Chalot, S., Victorelli, S., Spyridopoulos, I., Owens, A., Arthur, H. M., Passos, J. F., & Richardson, G. D. (2019) · Aging Cell · doi:10.1111/acel.12945 · Cited by 250
“K E Y W O R D S aging, cardiac, myocardial infarction, senescence, senolytics, survival secretory phenotype (SASP) (Coppe et al., 2008), which is pro‐in‐ flammatory, profibrotic and can also promote senescence in sur‐ rounding cells (Nelson et al., 2012).”
BackgroundChallenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
Motedayen Aval, L., Pease, J. E., Sharma, R., & Pinato, D. J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103323 · Cited by 248
Hoenicke, L., & Zender, L. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs124 · Cited by 248
Small molecule compounds that induce cellular senescence.
Petrova, N. V., Velichko, A. K., Razin, S. V., & Kantidze, O. L. (2016) · Aging Cell · doi:10.1111/acel.12518 · Cited by 240
RETRACTED: Chronic Inflammation: Accelerator of Biological Aging
Fougère, B., Boulanger, E., Nourhashémi, F., Guyonnet, S., & Cesari, M. (2017) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glw240 · Cited by 247
“First, drugs that suppress senescent cells, or eliminate their SASP, would allow to reduce chronic inflammation (98).”
BackgroundRetractedThe bystander effect contributes to the accumulation of senescent cells in vivo
da Silva, P. F. L., Ogrodnik, M., Kucheryavenko, O., Glibert, J., Miwa, S., Cameron, K., Ishaq, A., Saretzki, G., Nagaraja‐Grellscheid, S., Nelson, G., et al. (2019) · Aging Cell · doi:10.1111/acel.12848 · Cited by 247
“This was as expected given that we did not see induction of SASP at old age (Supporting information Figure S1D) and that numbers of senescent fibroblasts remaining in the tissue at 3 weeks after the last injection were as low as about 103 cells (Figure 3b).”
BackgroundInfluentialMalaquin, N., Martinez, A., & Rodier, F. (2016) · Experimental Gerontology · doi:10.1016/j.exger.2016.05.010 · Cited by 247
“The DNA damage response and stress-related signalling pathways ATM and the DNA damage response The SASP is initiated by all known varieties of genotoxic senescence-inducing stress (e.g. telomere shortening, cytotoxic drugs, radiation, oncogene activation, oxidative stress) (Coppe et al., 2008).”
InfluentialSelf-citationWiley, C. D., Flynn, J. M., Morrissey, C., Lebofsky, R., Shuga, J., Dong, X., Unger, M. A., Vijg, J., Melov, S., & Campisi, J. (2017) · Aging Cell · doi:10.1111/acel.12632 · Cited by 234
“This gene is induced in response to genotoxic stress in a p53-dependent manner (Sheikh et al., 1999) and is a component of the SASP (identified by its alias TRAILR3) (Coppe et al., 2008).”
BackgroundInfluentialTerlecki-Zaniewicz, L., Lämmermann, I., Latreille, J., Bobbili, M. R., Pils, V., Schosserer, M., Weinmüllner, R., Dellago, H., Skalicky, S., Pum, D., et al. (2018) · Aging · doi:10.18632/aging.101452 · Cited by 246
Sestrins induce natural killer function in senescent-like CD8+ T cells
Pereira, B. I., De Maeyer, R. P. H., Covre, L. P., Nehar-Belaid, D., Lanna, A., Ward, S., Marches, R., Chambers, E. S., Gomes, D. C. O., Riddell, N. E., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0643-3 · Cited by 245
Quantitative assessment of markers for cell senescence
Lawless, C., Wang, C., Jurk, D., Merz, A., Zglinicki, T. V., & Passos, J. F. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2010.01.018 · Cited by 240
Human trials exploring anti-aging medicines
Guarente, L., Sinclair, D. A., & Kroemer, G. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.007 · Cited by 244
Radiation effects on antitumor immune responses: current perspectives and challenges
Walle, T., Martinez Monge, R., Cerwenka, A., Ajona, D., Melero, I., & Lecanda, F. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017742575 · Cited by 243
A Senescence-Inflammatory Switch from Cancer-Inhibitory to Cancer-Promoting Mechanism
Pribluda, A., Elyada, E., Wiener, Z., Hamza, H., Goldstein, R. E., Biton, M., Burstain, I., Morgenstern, Y., Brachya, G., Billauer, H., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.005 · Cited by 239
“Heatmap colors indicate the bols are color-coded to indicate genes designated as SIR genes (red), SASP re (Acosta et al., 2008; Coppé et al., 2008; Kuilman et al., 2008; Kuilman and ted genes that showed at least 2-fold upregulation averaged in both conditions olated fromCKIaKOmice at different…”
BackgroundMethodResultInfluentialOxidative Stress Damage as a Detrimental Factor in Preterm Birth Pathology
Menon, R. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00567 · Cited by 240
“Although all four bases of DNA are susceptible to ROS-mediated alterations, hydroxylated nucleotide 8-hydroxy-deoxyguanine (8-OHdG) was for the first time referred to as a major product of oxidative DNA damage (see Glossary), and high concentrations of 8-OHdG in biological fluids are considered a biomarker of ROS (69–…”
BackgroundInfluentialChang, S., Yim, S., & Park, H. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0230-6 · Cited by 228
Cell Senescence: Role in Aging and Age-Related Diseases
Campisi, J., & Robert, L. (2014) · Interdisciplinary Topics in Gerontology and Geriatrics · doi:10.1159/000358899 · Cited by 240
Self-citationLong noncoding RNA Bmncr regulates mesenchymal stem cell fate during skeletal aging
Li, C.-J., Xiao, Y., Yang, M., Su, T., Sun, X., Guo, Q., Huang, Y., & Luo, X.-H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99044 · Cited by 238
“first quantitatively analyzed the factors secreted by senescent cells and proposed the concept of a senescence-associated secretory phenotype (SASP) consisting of cytokines, chemokines, growth factors, and proteases (31).”
Food as medicine: targeting the uraemic phenotype in chronic kidney disease
Mafra, D., Borges, N. A., Lindholm, B., Shiels, P. G., Evenepoel, P., & Stenvinkel, P. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00345-8 · Cited by 238
Senolytic therapies for healthy longevity.
van Deursen, J. M. (2019) · Science · doi:10.1126/science.aaw1299 · Cited by 237
RNA m6 A modification enzymes shape innate responses to DNA by regulating interferon β
Rubio, R. M., Depledge, D. P., Bianco, C., Thompson, L., & Mohr, I. (2018) · Genes & Development · doi:10.1101/gad.319475.118 · Cited by 236
“The cytoplasmic DNA sensor cGAS controls senescence, and senescent cells express greater levels of IFN β and proinflammatory cytokines as part of a senescence-associated secretory phenotype (SASP) (Coppé et al. 2008; Li and Chen 2018; Takahashi et al. 2018).”
Cellular senescence at the crossroads of inflammation and Alzheimer's disease
Guerrero, A., De Strooper, B., & Arancibia-Cárcamo, I. L. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2021.06.007 · Cited by 236
Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies
Wyld, L., Bellantuono, I., Tchkonia, T., Morgan, J., Turner, O., Foss, F., George, J., Danson, S., & Kirkland, J. L. (2020) · Cancers · doi:10.3390/cancers12082134 · Cited by 235
“Similarly, in prostate cancers treated with neoadjuvant mitozantrone, elevated levels of senescence biomarkers were found [31,63].”
BackgroundNicaise, A. M., Wagstaff, L. J., Willis, C. M., Paisie, C., Chandok, H., Robson, P., Fossati, V., Williams, A., & Crocker, S. J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818348116 · Cited by 233
Fibronectin in Cancer: Friend or Foe
Lin, T.-C., Yang, C.-H., Cheng, L.-H., Chang, W.-T., Lin, Y.-R., & Cheng, H.-C. (2019) · Cells · doi:10.3390/cells9010027 · Cited by 234
“In the beginning of oncogenic processes, pro-inflammatory cytokines in non-autonomous SASP [113,161], produced and secreted by the senescent parenchymal cells that suffer diversity of stresses, are essentially responsible for the alteration of surrounding microenvironments, including fibroblast activities [162,163].”
BackgroundSenescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Chen, H.-A., Ho, Y.-J., Mezzadra, R., Adrover, J. M., Smolkin, R., Zhu, C., Woess, K., Bernstein, N., Schmitt, G., Fong, L., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0528 · Cited by 230
Obesity and cancer pathogenesis
Berger, N. A. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12416 · Cited by 231
Estrada, J. C., Torres, Y., Benguría, A., Dopazo, A., Roche, E., Carrera-Quintanar, L., Pérez, R. A., Enríquez, J. A., Torres, R., Ramírez, J. C., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.211 · Cited by 231
“suggests that senescence in different human primary cells is associated with secretory phenotypes (SASP) that significantly increase the secretion of several proinflammatory chemoquines and cytoquines.(51,52) Our microarray gene expression analysis indicates that three main chemoquines are significantly downregulated…”
BackgroundSenescent cells: SASPected drivers of age-related pathologies
Ovadya, Y., & Krizhanovsky, V. (2014) · Biogerontology · doi:10.1007/s10522-014-9529-9 · Cited by 232
“The secretome include numerous cytokines, chemokines , growth factors, and proteases (Coppe et al. 2008); however, the exact composition may vary between cell types and induction stimuli.”
BackgroundGood Manufacturing Practices Production of Mesenchymal Stem/Stromal Cells
Sensebé, L., Bourin, P., & Tarte, K. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.197 · Cited by 233
“, 2009), stimulate cancer cell growth and invasion in vitro and in vivo (Coppé et al., 2008), and modulate the immune response and inflammation, although few data are available in this specific field.”
James, E. L., Michalek, R. D., Pitiyage, G. N., de Castro, A. M., Vignola, K. S., Jones, J., Mohney, R. P., Karoly, E. D., Prime, S. S., & Parkinson, E. K. (2015) · Journal of Proteome Research · doi:10.1021/pr501221g · Cited by 231
Plasma proteomic biomarker signature of age predicts health and life span
Tanaka, T., Basisty, N., Fantoni, G., Candia, J., Moore, A. Z., Biancotto, A., Schilling, B., Bandinelli, S., & Ferrucci, L. (2020) · eLife · doi:10.7554/elife.61073 · Cited by 213
Targeting innate immunity-driven inflammation in CKD and cardiovascular disease
Speer, T., Dimmeler, S., Schunk, S. J., Fliser, D., & Ridker, P. M. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00621-9 · Cited by 232
Glucocorticoids suppress selected components of the senescence‐associated secretory phenotype
Laberge, R., Zhou, L., Sarantos, M. R., Rodier, F., Freund, A., de Keizer, P. L. J., Liu, S., Demaria, M., Cong, Y., Kapahi, P., et al. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00818.x · Cited by 229
Self-citationFleury, H., Malaquin, N., Tu, V., Gilbert, S., Martinez, A., Olivier, M.-A., Sauriol, S. A., Communal, L., Leclerc-Desaulniers, K., Carmona, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10460-1 · Cited by 228
Self-citationWaldera Lupa, D. M., Kalfalah, F., Safferling, K., Boukamp, P., Poschmann, G., Volpi, E., Götz-Rösch, C., Bernerd, F., Haag, L., Huebenthal, U., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.120 · Cited by 224
Cellular Senescence and the Senescence-Associated Secretory Phenotype as Drivers of Skin Photoaging
Fitsiou, E., Pulido, T., Campisi, J., Alimirah, F., & Demaria, M. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.09.031 · Cited by 227
Self-citationMeasuring Aging and Identifying Aging Phenotypes in Cancer Survivors
Guida, J. L., Ahles, T. A., Belsky, D., Campisi, J., Cohen, H. J., DeGregori, J., Fuldner, R., Ferrucci, L., Gallicchio, L., Gavrilov, L., et al. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz136 · Cited by 216
Self-citationSenescence: a new weapon for cancer therapy
Acosta, J. C., & Gil, J. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.11.006 · Cited by 223
Tabibian, J. H., O'Hara, S. P., Trussoni, C. E., Tietz, P. S., Splinter, P. L., Mounajjed, T., Hagey, L. R., & LaRusso, N. F. (2016) · Hepatology · doi:10.1002/hep.27927 · Cited by 223
“, induce senescence in neighboring cells), and initiate profibroinflammatory and protumorigenic cellular responses and outcomes.(43,45,46) Therefore, we propose that the high proportion of senescent cholangiocytes observed in GF mdr2 mice represents both a marker as well as a driver of more severe hepatobiliary diseas…”
BackgroundWang, L., Leite de Oliveira, R., Wang, C., Fernandes Neto, J. M., Mainardi, S., Evers, B., Lieftink, C., Morris, B., Jochems, F., Willemsen, L., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.085 · Cited by 224
Targeting immune dysfunction in aging
Borgoni, S., Kudryashova, K. S., Burka, K., & de Magalhães, J. P. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101410 · Cited by 223
Two-Step Senescence-Focused Cancer Therapies
Sieben, C. J., Sturmlechner, I., van de Sluis, B., & van Deursen, J. M. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.04.006 · Cited by 222
Amor, C., Fernández-Maestre, I., Chowdhury, S., Ho, Y.-J., Nadella, S., Graham, C., Carrasco, S. E., Nnuji-John, E., Feucht, J., Hinterleitner, C., et al. (2024) · Nature Aging · doi:10.1038/s43587-023-00560-5 · Cited by 228
Cellular senescence: Immunosurveillance and future immunotherapy
Burton, D. G. A., & Stolzing, A. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.02.001 · Cited by 221
The ECM path of senescence in aging: components and modifiers
Levi, N., Papismadov, N., Solomonov, I., Sagi, I., & Krizhanovsky, V. (2020) · The FEBS Journal · doi:10.1111/febs.15282 · Cited by 219
Emerging roles of extracellular vesicles in cellular senescence and aging
Takasugi, M. (2018) · Aging Cell · doi:10.1111/acel.12734 · Cited by 222
Cell cycle arrest is not senescence
Blagosklonny, M. V. (2011) · Aging · doi:10.18632/aging.100281 · Cited by 217
“Senescent cells secrete both mitogenic and anti-mitogenic factors [16-27].”
BackgroundPilkington, S. M., Bulfone-Paus, S., Griffiths, C. E. M., & Watson, R. E. B. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.11.006 · Cited by 219
miR-21 and miR-146a: The microRNAs of inflammaging and age-related diseases
Olivieri, F., Prattichizzo, F., Giuliani, A., Matacchione, G., Rippo, M. R., Sabbatinelli, J., & Bonafè, M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101374 · Cited by 219
Aging in the dermis: Fibroblast senescence and its significance
Zhang, J., Yu, H., Man, M., & Hu, L. (2024) · Aging Cell · doi:10.1111/acel.14054 · Cited by 220
“These factors direct the cells to enter a state of irreversible growth arrest known as senescence (Colavitti & Finkel, 2005; Coppé et al., 2008).”
BackgroundRelevance of the p53–MDM2 axis to aging
Wu, D., & Prives, C. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.187 · Cited by 215
Senolytic agent Quercetin ameliorates intervertebral disc degeneration via the Nrf2/NF-κB axis
Shao, Z., Wang, B., Shi, Y., Xie, C., Huang, C., Chen, B., Zhang, H., Zeng, G., Liang, H., Wu, Y., et al. (2021) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2020.11.006 · Cited by 217
Changes in Regenerative Capacity through Lifespan
Yun, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161025392 · Cited by 216
“up-regulation of DNA checkpoint proteins such as p53, p21 and p16ink4a, rearrangements in nuclear architecture and heterochromatin organization, and the acquisition of a senescence-associated secretory phenotype (SASP) which comprises growth factors, proinflammatory cytokines, chemokines and matrix-remodelling protein…”
BackgroundSeverino, V, Alessio, N., Farina, A., Sandomenico, A., Cipollaro, M., Peluso, G., Galderisi, U., & Chambery, A. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.445 · Cited by 214
Chemokines in cancer related inflammation
Allavena, P., Germano, G., Marchesi, F., & Mantovani, A. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.11.013 · Cited by 215
“Cellular senescence can have a dual function in cancer progression, by favoring clearance of DNA damaged cells and in opposite direction by favoring progression of neighboring cells via secreted factors [84–86].”
BackgroundYoung, A. R. J., & Narita, M. (2009) · The EMBO Reports · doi:10.1038/embor.2009.22 · Cited by 214
“A series of recent papers (Acosta et al, 2008; Coppé et al, 2008; Kuilman et al, 2008; Wajapeyee et al, 2008), including one in this issue of EMBO reports by the group of David Bernard (Augert et al, 2009), have added various new members involved in SASP, and collectively reinforced the idea that…”
BackgroundResultInfluentialDifferent Facets of Aging in Human Mesenchymal Stem Cells
Wagner, W., Ho, A. D., & Zenke, M. (2010) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2009.0825 · Cited by 214
“41”
Cellular senescence: the sought or the unwanted?
Sun, Y., Coppé, J.-P., & Lam, E. W.-F. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.08.002 · Cited by 208
Self-citationLong noncoding RNAs (lncRNAs) and the molecular hallmarks of aging
Grammatikakis, I., Panda, A. C., Abdelmohsen, K., & Gorospe, M. (2014) · Aging · doi:10.18632/aging.100710 · Cited by 214
“Senescent cells actively secrete pro-inflammatory cytokines, a phenomenon known as the senescenceassociated secretory phenotype (SASP) [1, 175].”
BackgroundPeripheral immune system in aging and Alzheimer’s disease
Cao, W., & Zheng, H. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0284-2 · Cited by 214
Chen, H., Ruiz, P. D., McKimpson, W. M., Novikov, L., Kitsis, R. N., & Gamble, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.011 · Cited by 205
“Not all of the effects of SASP are tumor suppressive, as SASP has also been shown to promote cancer cell proliferation and invasion (Coppé et al., 2008; Krtolica et al., 2001; Liu and Hornsby, 2007).”
InfluentialMartínez‐Zamudio, R. I., Dewald, H. K., Vasilopoulos, T., Gittens‐Williams, L., Fitzgerald‐Bocarsly, P., & Herbig, U. (2021) · Aging Cell · doi:10.1111/acel.13344 · Cited by 213
“A large abundance of CD8+ T cells in peripheral blood of aged humans might therefore not only contribute to the increased susceptibility of the elderly to infections, but it might also impair clearance of senescent cells that accumulate in various tissues with age, accelerate development of systemic senescence through…”
BackgroundInfluentialKennedy, A. L., Morton, J. P., Manoharan, I., Nelson, D. M., Jamieson, N. B., Pawlikowski, J. S., McBryan, T., Doyle, B., McKay, C., Oien, K. A., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.02.020 · Cited by 213
“Prominently, senescent cells show a marked change in their secretory program (Coppe et al., 2008).”
Fletcher-Sananikone, E., Kanji, S., Tomimatsu, N., Di Cristofaro, L. F. M., Kollipara, R. K., Saha, D., Floyd, J. R., Sung, P., Hromas, R., Burns, T. C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0752 · Cited by 212
Hsp70 in cancer: back to the future
Sherman, M. Y., & Gabai, V. L. (2015) · Oncogene · doi:10.1038/onc.2014.349 · Cited by 211
Secreted microvesicular miR-31 inhibits osteogenic differentiation of mesenchymal stem cells
Weilner, S., Schraml, E., Wieser, M., Messner, P., Schneider, K., Wassermann, K., Micutkova, L., Fortschegger, K., Maier, A. B., Westendorp, R., et al. (2016) · Aging Cell · doi:10.1111/acel.12484 · Cited by 212
Transcriptional and epigenetic decoding of the microglial aging process
Li, X., Li, Y., Jin, Y., Zhang, Y., Wu, J., Xu, Z., Huang, Y., Cai, L., Gao, S., Liu, T., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00479-x · Cited by 207
“In addition, 3xDR microglia did not exhibit a different gene signature score of senescence-associated secretory phenotype (SASP) 112,113 from control microglia (Extended Data Fig.”
Glioma: molecular signature and crossroads with tumor microenvironment
Barthel, L., Hadamitzky, M., Dammann, P., Schedlowski, M., Sure, U., Thakur, B. K., & Hetze, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09997-9 · Cited by 211
“1 3 pro-cancerogenic activities of SASP [45].”
BackgroundInfluentialCharacterization of cellular senescence in aging skeletal muscle
Zhang, X., Habiballa, L., Aversa, Z., Ng, Y. E., Sakamoto, A. E., Englund, D. A., Pearsall, V. M., White, T. A., Robinson, M. M., Rivas, D. A., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00250-8 · Cited by 206
Impact of genomic damage and ageing on stem cell function
Behrens, A., van Deursen, J. M., Rudolph, K. L., & Schumacher, B. (2014) · Nature Cell Biology · doi:10.1038/ncb2928 · Cited by 207
Low abundance of the matrix arm of complex I in mitochondria predicts longevity in mice
Miwa, S., Jow, H., Baty, K., Johnson, A., Czapiewski, R., Saretzki, G., Treumann, A., & von Zglinicki, T. (2014) · Nature Communications · doi:10.1038/ncomms4837 · Cited by 206
“They secrete bioactive molecules including cytokines 57 and ROS 58 that can damage neighbouring cells 59 .”
Immunosurveillance of senescent cells: the bright side of the senescence program
Sagiv, A., & Krizhanovsky, V. (2013) · Biogerontology · doi:10.1007/s10522-013-9473-0 · Cited by 208
“Other chemokines such as RANTES (CCL5), ENA-78 (CXCL5), GCP-2 (CXCL6), CTACK (CCL27), I-309 (CCL1), MCP-3 (CCL7) and MIP-1b (CCL4), are also secreted, depending on cell type, cellular context and senescence stimuli (Coppe et al. 2008; Freund et al. 2010).”
BackgroundInfluentialOld Maids: Aging and Its Impact on Microglia Function
Koellhoffer, E., McCullough, L., & Ritzel, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040769 · Cited by 207
“In recent years, the senescence-associated secretory phenotype, or SASP, has been utilized to more accurately describe aged senescent cells, however these criteria may vary depending on cell type, especially as not all aged cells are senescent per se [27,28].”
BackgroundMethodCellular Senescence and Inflammaging in the Skin Microenvironment
Lee, Y. I., Choi, S., Roh, W. S., Lee, J. H., & Kim, T.-G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083849 · Cited by 204
“The acquired senescence-like phenotype in fibroblasts is indicated by the elevated levels of the cyclin-dependent kinases, p16INK4a and p21, and the tumor protein p53, and the expression of senescence-associated β-galactosidase (SA-β-gal), which are critically influenced by UVR [2].”
BackgroundInfluentialThe Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date
Oo, W. M., Little, C., Duong, V., & Hunter, D. J. (2021) · Drug Design, Development and Therapy · doi:10.2147/dddt.s295224 · Cited by 206
SASP: Tumor Suppressor or Promoter? Yes!
Rao, S. G., & Jackson, J. G. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.001 · Cited by 206
Takahashi, A., Imai, Y., Yamakoshi, K., Kuninaka, S., Ohtani, N., Yoshimoto, S., Hori, S., Tachibana, M., Anderton, E., Takeuchi, T., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2011.10.018 · Cited by 205
“Mo increase the expression of genes encoding a series of secreted proteins that alter local tissue environment and/or contribute to chronic inflammation (Acosta et al., 2008; Coppe et al., 2008; Kuilman et al., 2008).”
BackgroundInflammation and p53: A Tale of Two Stresses
Gudkov, A. V., Gurova, K. V., & Komarova, E. A. (2011) · Genes & Cancer · doi:10.1177/1947601911409747 · Cited by 205
“Aging tissues show gradual accumulation of senescent cells characterized by acquisition of the so-called pathological secretion phenotype, which is considered one of the important systemic pathological alterations accompanying, and possibly contributing to, aging.(105) NF-κB-driven transcription of cytokines and chemo…”
BackgroundA BET family protein degrader provokes senolysis by targeting NHEJ and autophagy in senescent cells
Wakita, M., Takahashi, A., Sano, O., Loo, T. M., Imai, Y., Narukawa, M., Iwata, H., Matsudaira, T., Kawamoto, S., Ohtani, N., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15719-6 · Cited by 206
Senolytics and senostatics as adjuvant tumour therapy
Short, S., Fielder, E., Miwa, S., & von Zglinicki, T. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.056 · Cited by 202
Role of sphingolipids in senescence: implication in aging and age-related diseases
Trayssac, M., Hannun, Y. A., & Obeid, L. M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97949 · Cited by 202
Small Extracellular Vesicles Have GST Activity and Ameliorate Senescence-Related Tissue Damage
Fafián-Labora, J. A., Rodríguez-Navarro, J. A., & O’Loghlen, A. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.004 · Cited by 203
Cartilage regeneration and ageing: Targeting cellular plasticity in osteoarthritis
Varela-Eirin, M., Loureiro, J., Fonseca, E., Corrochano, S., Caeiro, J. R., Collado, M., & Mayan, M. D. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2017.12.006 · Cited by 203
Hohmann, M. S., Habiel, D. M., Coelho, A. L., Verri, W. A., & Hogaboam, C. M. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0289oc · Cited by 202
The Cancer SENESCopedia: A delineation of cancer cell senescence
Jochems, F., Thijssen, B., De Conti, G., Jansen, R., Pogacar, Z., Groot, K., Wang, L., Schepers, A., Wang, C., Jin, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109441 · Cited by 201
“This raised the question of which SASP factors were expressed in the individual senescence models.”
BackgroundInfluentialStrategies targeting cellular senescence
Ovadya, Y., & Krizhanovsky, V. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95149 · Cited by 200
“These cells secrete a plethora of proinflammatory factors that assist in their removal by the immune system (19, 20).”
BackgroundSASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells
Canino, C., Mori, F., Cambria, A., Diamantini, A., Germoni, S., Alessandrini, G., Borsellino, G., Galati, R., Battistini, L., Blandino, R., et al. (2012) · Oncogene · doi:10.1038/onc.2011.485 · Cited by 200
New, J., Arnold, L., Ananth, M., Alvi, S., Thornton, M., Werner, L., Tawfik, O., Dai, H., Shnayder, Y., Kakarala, K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1077 · Cited by 199
Bone Aging, Cellular Senescence, and Osteoporosis
Pignolo, R. J., Law, S. F., & Chandra, A. (2021) · JBMR Plus · doi:10.1002/jbm4.10488 · Cited by 201
“(158) These collectively are referred to as the SASP.”
BackgroundInfluentialTherapeutic interventions for aging: the case of cellular senescence
Soto-Gamez, A., & Demaria, M. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.004 · Cited by 192
Menon, R., Boldogh, I., Hawkins, H. K., Woodson, M., Polettini, J., Syed, T. A., Fortunato, S. J., Saade, G. R., Papaconstantinou, J., & Taylor, R. N. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.02.011 · Cited by 196
Cellular Senescence in Postmitotic Cells: Beyond Growth Arrest
Sapieha, P., & Mallette, F. A. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.03.003 · Cited by 193
The Cellular and Molecular Basis of Translational Immunometabolism
Norata, G. D., Caligiuri, G., Chavakis, T., Matarese, G., Netea, M. G., Nicoletti, A., O’Neill, L. A. J., & Marelli-Berg, F. M. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.023 · Cited by 196
“Far from being inert, senescent T cells exhibit potent effector functions, secrete high levels of both TNF-a and IFN-g, and display potent cytotoxic activity (Coppé et al., 2008; Henson and Akbar, 2010; Henson et al., 2014), for which they require active metabolism.”
BackgroundInfluential
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.